Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.

In a pooled mediation analysis of the FIDELIO-DKD and FIGARO-DKD trials, early finerenone-induced reduction in albuminuria accounted for a large share of the kidney protection but only a modest share of the cardiovascular benefit in patients with CKD and type 2 diabetes.